TP53 tumour suppressor gene: Clues to molecular carcinosenesis and cancer therapy

Cancer Surveys

Volumn 28, Issue , 1996, Pages 169-196

  Wang, Xin W ^a   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ONCOPROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR;

AMINO TERMINAL SEQUENCE; APOPTOSIS; CANCER DIAGNOSIS; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; DNA SEQUENCE; EXCISION REPAIR; FAMILIAL CANCER; GENE MUTATION; GENETIC STABILITY; GENETIC SUSCEPTIBILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; VIRUS GENE;

ANIMALS; APOPTOSIS; CELL DIVISION; DNA REPAIR; GENES, P53; HUMANS; LI-FRAUMENI SYNDROME; MICE; MUTATION; NEOPLASMS; PHOSPHORYLATION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030442972     PISSN: 02612429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (230)

1. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proceedings of the National Academy of Sciences of the USA 92 8493-8497
2. Aguilar F, Hussain SP and Cerutti P (1993) Aflatoxin B1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proceedings of the National Academy of Sciences of the USA 90 8586-8590
3. Ahuja H, Bar-Eli M, Advani SH, Benchimol S and Cline MJ (1989) Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proceedings of the National Academy of Sciences of the USA 86 6783-6787
4. Almon E, Goldfinger N, Kapon A, Schwarte D, Levine AJ and Rotter V (1993) Testicular tissue-specific expression of the p53 suppressor gene. Developmental Biology 156 107-116
5. Armstrong JF, Kaufman MH, Harrison DJ and Clarke AR (1995) High-frequency developmental abnormalities in p53-deficient mice. Current Biology 5 931-937
6. Bakalkin G, Yakovleva T, Selivanova G et al (1994) p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proceedings of the National Academy of Sciences of the USA 91 413-417
7. Baker SJ, Fearon ER, Nigro JM et al (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244 217-221
8. Baker SJ, Markowitz S, Fearon ER, Willson JK and Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249 912-915
9. Barak Y, Juven T, Haffner R and Oren M (1993) mdm2 expression is induced by wild type p53 activity. EMBO Journal 12 461-468
10. Bargonetti J, Friedman PN, Kern SE, Vogelstein B and Prives C (1991) Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65 1083-1091
11. Baudier J, Delphin C, Grunwald D, Khochbin S and Lawrence JJ (1992) Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. Proceedings of the National Academy of Sciences of the USA 89 11627-11631
12. Bayle JH, Elenbaas B and Levine AJ (1995) The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proceedings of the National Academy of Sciences of the USA 92 5729-5733
13. Bazar LS and Deeg HJ (1992) Ultraviolet B-induced DNA fragmentation (apoptosis) in activated T-lymphocytes and Jurkat cells is augmented by inhibition of RNA and protein synthesis. Experimental Hematology 20 80-86
14. Bell DA, Taylor JA, Butler MA et al (1993) Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 14 1689-1692
15. Bienz-Tadmor B, Zakut-Houri R, Libresco S, Givol D and Oren M (1985) The 5′ region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element. EMBO Journal 4 3209-3213
16. Bischoff JR, Friedman PN, Marshak DR, Prives C and Beach D (1990) Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proceedings of the National Academy of Sciences of the USA 87 4766-4770
17. Bissonnette RP, Echeverri F, Mahboubi A and Green DR (1992) Apoptotic cell death induced by c- myc is inhibited by bcl-2. Nature 359 552-554
18. Bouffler SD, Kemp CJ, Balmain A and Cox R (1995) Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice. Cancer Research 55 3883-3889
19. Bressac B, Kew M, Wands J and Ozturk M (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350 429-431
20. Buckbinder L, Talbott R, Velasco-Miguel S et al (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377 646-649
21. Caelles C, Helmberg A and Karin M (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370 220-223
22. Cannon CE, Golmer TM, Courts SB and Kastan MB (1995) Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes and Development 9 600-611
23. Chen PL, Chen Y, Bookstein R and Lee WH (1991) Genetic mechanisms of tumor suppression by the human p53 gene. Science 250 1576-1580
24. Chen X, Farmer G, Zhu H, Prywes R and Prives C (1993) Cooperative DNA binding of p53 with TFIID (TBP): a possible mechanism for transcriptional activation. Genes and Development 7 1837-1849 (erratum 1993 7 2652)
25. Chin KV, Ueda K, Pastan I and Gottesman MM (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255 459-462
26. Cho Y, Gorina S, Jeffrey P and Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: a framework for understanding how mutations inactivate p53. Science 265 346-355
27. Clore GM, Omichinski JG, Sakaguchi K et al (1994) High-resolution solution structure of the oligomerization domain of p53 by multi-dimensional NMR. Science 265 386-391
28. Crook T, Marston NJ, Sara EA and Vousden KH (1994) Transcriptional activation by p53 correlates with suppression of growth-but not transformation. Cell 79 817-827
29. Cross SM, Sanchez CA, Morgan CA et al (1995) A p53-dependent mouse spindle checkpoint. Science 267 1353-1356
30. Dameron KM, Volpert OV, Tainsky MA and Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265 1582-1584.
31. Debbas M and White E (1993) Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes and Development 7 546-554
32. Deffie A, Wu H, Reinke V and Lozano G (1993) The tumor suppressor p53 regulates its own transcription. Molecular and Cellular Biology 13 3415-3423
33. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW and Old LJ (1979) Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proceedings of the National Academy of Sciences of the USA 76 2420-2424
34. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82 675-684
35. Diller L, Kassel J, Nelson CE et al (1990) p53 functions as a cell cycle control protein in osteosarcomas. Molecular and Cellular Biology 10 5772-5781
36. Dittmer D, Pati S, Zambetti G et al (1993) Gain of function mutations in p53. Nature Genetics 4 42-46
37. Donehower LA, Harvey M, Slagle BL et al (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 215-221
38. Dutta A, Ruppert JM, Aster JC and Winchester E (1993) Inhibition of DNA replication factor RPA by p53. Nature 365 79-82
39. Dyson N, Howley PM, Munger K and Harlow E (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243 934-937
40. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B (1992) Definition of a consensus binding site for p53. Nature Genetics 1 45-49
41. El-Deiry WS, Tokino T, Velculescu VE et al (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75 817-825
42. El-Deiry WS, Harper JW, O'Connor PM et al (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Research 54 1169-1174
43. Eliyahu D, Raz A, Gruss P, Givol D and Oren M (1984) Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312 646-649
44. Eliyahu D, Michalovitz D and Oren M (1985) Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 316 158-160
45. Eliyahu D, Goldfinger N, Pinhasi-Kimhi O et al (1988) Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene 3 313-321
46. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O and Oren M (1989) Wild-type p53 can inhibit oncogene-mediated focus formation. Proceedings of the National Academy of Sciences of the USA 86 8763-8767
47. Ellis NA, Groden J, Ye TZ et al (1995) The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 83 655-666
48. Evan GI, Wyllie AH, Gilbert CS et al (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell 69 119-128
49. Fakharzadeh SS, Trusko SP and George DL (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO Journal 10 1565-1569
50. Feitelson MA, Zhu M, Duan LX and London WT (1993) Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8 1109-1117
51. Fields S and Jang SK (1990) Presence of a potent transcription activating sequence in the p53 protein. Science 249 1046-1048
52. Finlay CA (1993) The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Molecular and Cellular Biology 13 301-306
53. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M and Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Molecular and Cellular Biology 8 531-539
54. Finlay CA, Hinds PW and Levine AJ (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57 1083-1093
55. Fiscella M, Ullrich SJ, Zambrano N et al (1993) Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 8 1519-1528
56. Flejter WL, McDaniel LD, Johns D, Friedberg EC and Schulte RA (1992) Correction of xeroderma pigmentosum complementation group D mutant cell phenotypes by chromosome and gene transfer: involvement of the human ERCC2 DNA repair gene. Proceedings of the National Academy of Sciences of the USA 89 261-265
57. Foord O, Bhattacharya P, Reich Z and Rotter V (1991) A DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucleic Acids Research 19 5191-5198
58. Foord O, Navot N and Rotter V (1993) Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein. Molecular and Cellular Biology 13 1378-1384
59. Ford JM and Hanawalt PC (1995) Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV-resistance. Proceedings of the National Academy of Sciences of the USA 92 8876-8880
60. Forrester K, Ambs S, Lupold SE et al (1996) Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase (NOS2) expression by wild-type p53. Proceedings of the National Academy of Sciences of the USA 93 2442-2447
61. Frebourg T, Kassel J, Lam KT et al (1992) Germline mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proceedings of the National Academy of Sciences of the USA 89 6413-6417
62. Fuchs B, O'Connor D, Fallis L, Scheidtmann KH and Lu X (1995) p53 phosphorylation mutants retain transcription activity. Oncogene 10 789-793
63. Funk WD, Pak DT, Karas RH, Wright WE and Shay JW (1992) A transcriptionally active DNA-binding site for human p53 protein complexes. Molecular and Cellular Biology 12 2866-2871
64. Gannon JV, Greaves R, Iggo R and Lane DP (1990) Activating mutations in p53 produce a common conformational effect: a monoclonal antibody specific for the mutant form. EMBO Journal 9 1595-1602
65. Ginsberg D, Mechta F, Yaniv M and Oren M (1991) Wild-type p53 can down-modulate the activity of various promoters. Proceedings of the National Academy of Sciences of the USA 88 9979-9983
66. Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Research 54 4855-4878
67. Greenblatt MS, Grollman AP and Harris CC (1996) Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/ misalignment model. Cancer Research 56 2130-2136
68. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B and Liebermann DA (1995) p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 10 2263-2270
69. Hall PA, Ray A, Lemoine NR, Midgley CA, Krausz T and Lane DP (1991) p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 338 513
70. Harlow E, Williamson NM, Ralston R, Helfman DM and Adams TE (1985) Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Molecular and Cellular Biology 5 1601-1610
71. Harris CC (1993) p53: at the crossroads of molecular carcinogenesis and cancer risk assessment. Science 262 1980-1981
72. Harris CC (1996a) Molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour suppressor gene. British Journal of Cancer 73 261-269
73. Harris CC (1996b) p53 tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis 17: 1187-1198
74. Harris CC and Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. New England Journal of Medicine 329 1318-1327
75. Harris CC, Grady H and Svoboda D (1968) Alterations in pancreatic and hepatic ultrastructure following acute cycloheximide intoxication. Journal of Ultrastructure Research 22 240-251
76. Harvey M, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A and Donehower LA (1993) Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genetics 5 225-229
77. Haupt Y, Rowan S, Shaulian E, Vousden KH and Oren M (1995) Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes and Development 9 2170-2183
78. Havre PA, Yuan J, Hedrick L, Cho KR and Glazer PM (1995) p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Research 55 4420-4424
79. He Z, Brinton BT, Greenblatt J, Hassell JA and Ingles CJ (1993) The transactivator proteins VP16 and GAL4 bind replication factor A. Cell 73 1223-1232
80. Hermeking H and Eick D (1994) Mediation of c-Myc-induced apoptosis by p53. Science 265 2091-2093
81. Hinds PW, Finlay CA, Frey AB and Levine AJ (1987) Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Molecular and Cellular Biology 7 2863-2869
82. Hinds P, Finlay C and Levine AJ (1989) Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. Journal of Virology 63 739-746
83. Hollstein MC, Peri L, Mandard AM et al (1991a) Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. Cancer Research 51 4102-4106
84. Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991b) p53 mutations in human cancers. Science 253 49-53
85. Hollstein M, Shomer B, Greenblatt M et al (1996) Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Research 24 141-146
86. Hsiao M, Low J, Dom E et al (994) Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. American Journal of Pathology 145 702-714
87. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ and Harris CC (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350 427-428
88. Hupp TR and Lane DP (1994) Allosteric activation of latent p53 tetramers. Current Biology 4 865-875
89. Hupp TR, Meek DW, Midgley CA and Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71 875-886
90. Hupp TR, Meek DW, Midgley CA and Lane DP (1993) Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Research 21 3167-3174
91. Hupp TR, Sparks A and Lane DP (1995) Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83 237-245
92. Itoh N, Yonehara S, Ishii A et al (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66 233-243
93. Jacks T, Remington L, Williams B, Schmitt E, Halachmi S, Bronson R and Weinberg R (1994) Tumor spectrum analysis in p53-mutant mice. Current Biology 4 1-7
94. Jayaraman L and Prives C (1995) Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81 1021-1029
95. Jenkins JR, Rudge K and Currie GA (1984) Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 312 651-654
96. Kastan MB, Zhan Q, El-Deiry WS et al (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71 587-597
97. Kelley LL, Green WF, Hicks GG, Bondurant MC, Koury MJ and Ruley HE (1994) Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the G1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53. Molecular and Cellular Biology 14 4183-4192
98. Kemp CJ, Donehower LA, Bradley A and Balmain A (1993) Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74 813-822
99. Kemp CJ, Wheldon T and Balmain A (1994) p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genetics 8 66-69
100. Kern SE, Kinzler KW, Bruskin A et al (1991) Identification of p53 as a sequence-specific DNA-binding protein. Science 252 1708-1711
101. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW and Vogelstein B (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256 827-830
102. Kerr JF, Wyllie AH and Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British Journal of Cancer 26 239-257
103. Kitayama H, Sugimoto Y, Matsuzaki T, Ikawa Y and Noda M (1989) A ras-related gene with transformation suppressor activity. Cell 56 77-84
104. Kley N, Chung RY, Fay S, Loeffler JP and Seizinger BR (1992) Repression of the basal c-fos promoter by wild-type p53. Nucleic Acids Research 20 4083-4087
105. Kress M, May E, Cassingena R and May P (1979) Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. Journal of Virology 31 472-483
106. Lane DP and Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278 261-263
107. Leach FS, Tokino T, Meltzer P et al (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Research 53 2231-2234
108. Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH and Laimins LA (1992) Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO Journal 11 3045-3052 (erratum 1992 11 4248)
109. Lee JM and Bernstein A (1993) p53 mutations increase resistance to ionizing radiation. Proceedings of the National Academy of Sciences of the USA 90 5742-5746
110. Lee S, Elenbase B, Levine A and Griffith J (1995) p53 and its 14kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81 1013-1020
111. Lees-Miller SP, Chen Y-R and Anderson CW (1990) Human cells contain a DNA-activated protein kinase that phosphorylates simian virus 40 T antigen, mouse p53, and the human Ku autoantigen. Molecular and Cellular Biology 10 6472-6481
112. Levine AJ, Momand J and Finlay CA (1991) The p53 tumour suppressor gene. Nature 351 453-456
113. Li FP (1990) Familial cancer syndromes and clusters. Current Problems in Cancer 14 73-114
114. Li R and Botchan MR (1993) The acidic transcriptional activation domains of VP16 and p53 bind the cellular replication protein A and stimulate in vitro BPV-1 DNA replication. Cell 73 1207-1221
115. Li G, Mitchell DL, Ho VC, Reed JC and Tron VA (1996) Decreased DNA repair but normal apoptosis in UV-irradiated skin of p53 transgenic mice. American Journal of Pathology 148 1113-1123
116. Lin D, Shields MT, Ullrich SJ, Appella E and Mercer WE (1992) Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proceedings of the National Academy of Sciences of the USA 89 9210-9214
117. Lin J, Chen J, Elenbaas B and Levine AJ (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes and Development 8 1235-1246
118. Linzer DI and Levine AJ (1979) Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17 43-52
119. Liu X, Miller CW, Koeffler PH and Berk AJ (1993) The p53 activation domain binds the TATA box-binding polypeptide in holo-TFIID, and a neighboring p53 domain inhibits transcription. Molecular and Cellular Biology 13 3291-3300
120. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70 923-935
121. Lowe SW and Ruley HE (1993) Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes and Development 7 535-545
122. Lowe SW, Ruley HE, Jacks T and Housman DE (1993a) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 957-967
123. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T (1993b) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362 847-849
124. Lowe SW, Bodis S, McClatchey A et al (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266 807-810
125. Lu H and Levine AJ (1995) Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proceedings of the National Academy of Sciences of the USA 92 5154-5158
126. Lu X and Lane DP (1993) Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75 765-778
127. McCarthy SA, Symonds HS and Van Dyke T (1994) Regulation of apoptosis in transgenic mice by simian virus 40 T antigen-mediated inactivation of p53. Proceedings of the National Academy of Sciences of the USA 91 3979-3983
128. Mackay J, Steel CM, Elder PA, Forrest AP and Evans HJ (1988) Allele loss on short arm of chromosome 17 in breast cancers. Lancet ii 1384-1385
129. Macleod KF, Sherry N, Hannon G et al (1995) p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes and Development 9 935-944
130. McWhir J, Selfridge J, Harrison DJ, Squires S and Melton DW (1993) Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning. Nature Genetics 5 217-224
131. Maheswaran S, Park S, Bernard A et al (1993) Physical and functional interaction between WT1 and p53 proteins. Proceedings of the National Academy of Sciences of the USA 90 5100-5104
132. Malkin D, Li FP, Strong LC et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 1233-1238
133. Malkin D, Jolly KW, Piraux NB et al (1992) Germline mutations of the p53 tumor suppressor gene in children and young adults with second malignant neoplasms. New England Journal of Medicine 326 1309-1315
134. + T cell blasts. Immunology Letters 35 125-134
135. Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L and Benchimol S (1984) Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO Journal 3 3257-3262
136. Meek DW, Simon S, Kikkawa U and Eckhart W (1990) The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. EMBO Journal 9 3253-3260
137. Mercer WE, Shields MT, Amin M et al (1990) Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proceedings of the National Academy of Sciences of the USA 87 6166-6170
138. Mercer WE, Shields MT, Lin D, Appella E and Ullrich SJ (1991) Growth suppression induced by wild type p53 protein is accompanied by selective down regulation of proliferating cell nuclear antigen (PCNA) expression. Proceedings of the National Academy of Sciences of the USA 88 1958-1962
139. Meyn MS, Strasfeld L and Allen C (1994) Testing the role of p53 in the expression of genetic instability and apoptosis in ataxia-telangiectasia. Interational Journal of Radiation Biology 66 S141-S149
140. Mietz JA, Unger T, Huibregtse JM and Howley PM (1992) The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO Journal 11 5013-5020
141. Milne DM, Campbell DG, Caudwell FB and Meek DW (1994) Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases. Journal of Biological Chemistry 269 9253-9260
142. Milne DM, Campbell LE, Campbell DG and Meek DW (1995) p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. Journal of Biological Chemistry 270 5511-5518
143. Miyashita T and Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80 293-299
144. Miyashita T, Harigai M, Hanada M and Reed JC (1994a) Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Research 54 3131-3135
145. Miyashita T, Krajewski S, Krajewska M et al (1994b) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9 1799-1805
146. Momand J, Zambetti GP, Olson DC, George D and Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 1237-1245
147. Nelson WG and Kastan MB (1994) DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Molecular and Cellular Biology 14 1815-1823
148. Nigro JM, Baker SJ, Preisinger AC et al (1989) Mutations in the p53 gene occur in diverse human tumor types. Nature 342 705-708
149. Nijman HW, van der Burg SH, Vierboom MP, Houbiers JG, Kast WM and Melief CJ (1994) p53, a potential target for tumor-directed T cells. Immunology Letters 40 171-178
150. Oberosler P, Hloch P, Ramsperger U and Stahl H (1993) p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO Journal 12 2389-2396
151. Ogawa T, Yu X, Shinohara A and Egelman EH (1993) Similarity of the yeast RAD51 filament to the bacterial RecA filament. Science 259 1896-1899
152. Okamoto K and Beach D (1994) Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO Journal 13 4816-4822
153. Oliner JD, Kinzler KW, Meltzer PS, George DL and Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358 80-83
154. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW and Vogelstein B (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362 857-862
155. Oltvai ZN, Milliman CL, and Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 609-619
156. Oren M and Levine AJ (1983) Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proceedings of the National Academy of Sciences of the USA 80 56-59
157. O'Rourke RW, Miller CW, Kato GJ et al (1990) A potential transcriptional activation element in the p53 protein. Oncogene 5 1829-1832
158. Owen-Schaub LB, Zhang W, Cusack JC et al (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Molecular and Cellular Biology 15 3032-3040
159. Parada LF, Land H, Weinberg RA, Wolf D and Rotter V (1984) Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312 649-651
160. Pietenpol JA and Vogelstein B (1993) Tumour suppressor genes: no room at the p53 inn. Nature 36517-18
161. Pietenpol JA, Tokino T, Thiagalingam S, El-Deiry WS, Kinzler KW and Vogelstein B (1994) Sequence-specific transcriptional activation is essential for growth suppression by p53. Proceedings of the National Academy of Sciences of the USA 91 1998-2002
162. Pinhasi-Kimhi O, Michalovitz D, Ben-Zeev A and Oren M (1986) Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature 320 182-184
163. Pohl J, Lehmann V, Radler-Pohl A and Schirrmacher V (1989) Induction of the metastatic phenotype by transfection of the nuclear oncogene p53: increases in cytoplasmic diacylglycerol levels and reduction in class I major histocompatibility antigen expression are not sufficient to explain the changes in metastatic capacities. Journal of Cancer Research and Clinical Oncology 115 145-147
164. Powell SN, DeFrank JS, Connell P et al (1995) Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Research 55 1643-1648
165. Prives C (1994) How loops, beta sheets, and alpha helices help us to understand p53. Cell 78 543-546
166. Qin XQ, Livingston DM, Kaelin Jr WG and Adams PD (1994) Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proceedings of the National Academy of Sciences of the USA 91 10918-10922
167. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y and Jacobson MD (1993) Programmed cell death and the control of cell survival: lessons from the nervous system. Science 262 695-700
168. Raycroft L, Wu H and Lozano G (1990) Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249 1049-1051
169. Ross RK, Yuan JM, Yu MC et al (1992) Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339 943-946
170. Rotter V, Schwartz D, Almon E et al (1993) Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proceedings of the National Academy of Sciences of the USA 90 9075-9079
171. Rovinski B and Benchimol S (1988) Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene 2 445-452
172. Rowan S, Ludwig RL, Haupt Y et al (1996) Specific loss of apoptotic but not cell cycle arrest function in a human tumour derived p53 mutant. EMBO Journal 15 827-838
173. Sabbatini P, Lin J, Levine AJ and White E (1995) Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes and Development 9 2184-2192
174. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT and Jacks T (1995) A subset of p53-deficient embryos exhibit exencephaly. Nature Genetics 10 175-180
175. Santhanam U, Ray A and Sehgal PB (1991) Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proceedings of the National Academy of Sciences of the USA 88 7605-7609
176. Sarnow P, Ho YS, Williams J and Levine AJ (1982) Adenovirus Elb-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell. 28 387-394
177. Savitsky K, Bar-Shira A, Gilad S et al (1995) A single ataxia-telangiectasia gene with a product similar to Pi-3 kinase. Science 268 1749-1753
178. Scharer E and Iggo R (1992) Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Research 20 1539-1545
179. Schmid P, Lorenz A, Hameister H and Montenarh M (1991) Expression of p53 during mouse embryogenesis. Development 113 857-865
180. Schwartz D, Goldfinger N and Rotter V (1993) Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes. Oncogene 8 1487-1494
181. Seto E, Usheva A, Zambetti GP et al (1992) Wild-type p53 binds to the TATA-binding protein and represses transcription. Proceedings of the National Academy of Sciences of the USA 89 12028-12032
182. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B and Costa J (1992) Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proceedings of the National Academy of Sciences of the USA 89 4495-4499
183. Shiio Y, Yamamoto T and Yamaguchi N (1992) Negative regulation of Rb expression by the p53 gene product. Proceedings of the National Academy of Sciences of the USA 89 5206-5210
184. Shin TH, Paterson AJ and Kudlow JE (1995) p53 stimulates transcription from the human transforming growth factor alpha promoter: a potential growth-stimulatory role for p53. Molecular and Cellular Biology 15 4694-4701
185. Shinohara A, Ogawa H and Ogawa T (1992) Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein. Cell 69 457-470 (erratum 1992 7 180)
186. Shinohara A, Ogawa H, Matsuda Y, Ushio N, Ikeo K and Ogawa T (1993) Cloning of human, mouse and fission yeast recombination genes homologous to RAD51 and recA. Nature Genetics 4 239-243 (erratum 1993 5 312)
187. Smith ML, Chen IT, Zhan Q, O'Connor PM and Fornace Jr AJ (1995) Involvement of the p53 tumor suppressor in repair of UV-type DNA damage. Oncogene 10 1053-1059
188. Soussi T, Legros Y, Lubin R, Ory K and Schlichtholz B (1994) Multifactorial analysis of p53 alteration in human cancer: a review. International Journal of Cancer 57 1-9
189. Speir E, Modali R, Huang ES et al (1994) Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265 391-394
190. Srivastava S, Zou ZQ, Pirollo K, Blattner W and Chang EH (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348 747-749
191. Stewart N, Hicks GG, Paraskevas F and Mowat M (1995) Evidence for a second cell cycle block at G2/M by p53. Oncogene 10 109-115
192. Sturzbecher HW, Chumakov P, Welch WJ and Jenkins JR (1987) Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40-transformed monkey cells. Oncogene 1 201-211
193. Sturzbecher HW, Brain R, Addison C et al (1992) A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7 1513-1523
194. Sturzbecher H-W, Donzelmann B, Henning W, Knippschild U and Buchhop S (1996) p53 is directly linked to homologous recombination processes via RAD51/RecA protein interaction. EMBO Journal 15 1992-2002
195. Symonds H, Krall L, Remington L et al (1994) p53-Dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78 703-711
196. Szekely L, Selivanova G, Magnusson KP, Klein G and Wiman KG (1993) EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proceedings of the National Academy of Sciences of the USA 90 5455-5459
197. Takahashi T, Nau MM, Chiba I et al (1989) p53: a frequent target for genetic abnormalities in lung cancer. Science 246 491-494
198. Takenaka I, Morin F, Seizinger BR and Kley N (1995) Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. Journal of Biological Chemistry 270 5405-5411
199. Thut CJ, Chen J-L, Klemm R and Tjian R (1995) p53 transcriptional activation mediated by coactivators TAFii40 and TAFii60. Science 267 100-104
200. Troelstra C, van Gool A, de Wit J, Vermeiden W, Bootsma D and Hoeijmakers JH (1992) ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes. Cell 71 939-953
201. Truant R, Xiao H, Ingles CJ and Greenblatt J (1993) Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. Journal of Biological Chemistry 268 2284-2287
202. Ueda H, Ullrich SJ, Gangemi JD et al (1995) Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genetics 9 41-47
203. Vogelstein B and Kinzler KW (1992) p53 function and dysfunction. Cell 70 523-526
204. Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. New England Journal of Medicine 319 525-532
205. Wagner AJ, Kokontis JM and Hay N (1994) Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes and Development 8 2817-2830
206. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR and Harris CC (1994) Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proceedings of the National Academy of Sciences of the USA 91 2230-2234
207. Wang XW, Gibson MK, Vermeiden W et al (1995a) Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Research 55 6012-6016
208. Wang XW, Yeh H, Schaeffer L et al (1995b) p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genetics 10 188-195
209. Wang XW, Vermeulen W, Coursen JD et al (1996) The XPB and XPD helicases are components of the p53-mediated apoptosis pathway. Genes and Development 10 1219-1232
210. Wang Y and Prives C (1995) Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376 88-91
211. Weeda G, van Ham RC, Vermeulen W, Bootsma D, van der Eb AJ and Hoeijmakers JH (1990) A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne's syndrome. Cell 62 777-791
212. Weintraub H, Hauschka S and Tapscott SJ (1991) The MCK enhancer contains a p53 responsive element. Proceedings of the National Academy of Sciences of the USA 88 4570-4571
213. Weston A, Willey JC, Modali R et al (1989) Differential DNA sequence deletions from chromosomes 3, 11, 13 and 17 in squamous cell carcinoma, large cell carcinoma and adenocarcinoma of the human lung. Proceedings of the National Academy of Sciences of the USA 86 5099-5103
214. Wiedenfeld EA, Fernandez-Vina M, Berzofsky JA and Carbone DP (1994) Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA (Currency sign), 0201 peptide consensus motif. Cancer Research 54 1175-1177
215. Wolf D, Harris N and Rotter V (1984) Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell 38 119-126
216. Wolkowicz R, Peled A, Elkind NB and Rotter V (1995) Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal aternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form. Proceedings of the National Academy of Sciences of the USA 92 6842-6846
217. Wu X and Levine AJ (1994) p53 and E2F-1 cooperate to mediate apoptosis. Proceedings of the National Academy of Sciences of the USA 91 3602-3606
218. Wu Y, Liu Y, Lee L, Miner Z and Kulesz-Martin M (1994) Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO Journal 13 4823-4830
219. Wu-Williams AH, Zeise L and Thomas D (1992) Risk assessment for aflatoxin B1: a modeling approach. Risk Analysis 12 559-567
220. Wyllie AH (1994) Apoptosis: death gets a brake. Nature 369 272-273
221. Xiao H, Pearson A, Coulombe B et al (1994) Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Molecular and Cellular Biology 14 7013-7024
222. Yew PR and Berk AJ (1992) Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 357 82-85
223. Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70 937-948
224. Yokota J, Wada M, Shimosato Y, Terada M and Sugimura T (1987) Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proceedings of the National Academy of Sciences of the USA 84 9252-9256
225. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352 345-347
226. Yonish-Rouach E, Grunwald D, Wilder S et al (1993) p53-mediated cell death: relationship to cell cycle control. Molecular and Cellular Biology 13 1415-1423
227. Yue QY, Bertilsson L, Dahl-Puustinen ML et al (1989) Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet ii 870
228. Zakut-Houri R, Oren M, Bienz B, Lavie V, Hazum S and Givol D (1983) A single gene and a pseudogene for the cellular tumour antigen p53. Nature 306 594-597
229. Zambetti GP, Bargonetti J, Walker K, Prives C and Levine AJ (1992) Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes and Development 6 1143-1152
230. Zhan Q, Lord KA, Alamo Jr I et al (1994) The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Molecular and Cellular Biology 14 2361-2371